BOULDER, Colo .– (BUSINESS WIRE) – Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. announced the closing of a $ 11.4 million financing led by Telegraph Hill Partners (“THP”), a life science venture capital and growth equity firm based in San Francisco, CA. Dan Mitchell, a Boulder-based venture capitalist, also participated in the financing.
Mosaic provides its partners experienced leadership and biopharma research teams to drive discovery and development of protein therapies from concept through preclinical development. The Company works collaboratively with its partners to extend their research capabilities and accelerate their development programs. Mosaic’s capabilities streamline protein and antibody therapeutic programs, reduce timelines and costs, and successfully advance programs through the completion of key discovery and early development milestones.
The growth financing will be used to expand lab facility infrastructure, develop new technologies and capabilities, augment the business development team, and expand the breadth of Mosaic’s scientific team to meet the evolving needs for protein and antibody therapeutic discovery services.
“We are excited to partner with the THP team as we work to build the preeminent company for the discovery of protein and antibody therapeutics,” said Marty Stanton, Chief Executive and Operating Officer at Mosaic Biosciences. “We are committed to providing a wide breadth of discovery capabilities to help our partners bring transformative therapies to their patients.”
“Mosaic brings CSO-caliber expertise and experienced biopharmaceutical research teams to design, guide, execute, and manage drug programs for their partners who are focused on discovering innovative medicines,” said Jeanette Welsh, Partner at Telegraph Hill Partners. “We look forward to working with the full Mosaic team to address the critical need for solving challenging problems in therapeutic discovery.” Jeanette Welsh and Rob Capone from Telegraph Hill Partners will join Mosaic’s board concurrent with the financing, and Deval Lashkari from Telegraph Hill Partners will join as a Board observer. Dan Mitchell and Eric Furfine, Chief Executive and Scientific Officer at Mosaic, will also hold seats on the Mosaic Board.
About Mosaic Biosciences:
Mosaic is a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. Mosaic teams provide comprehensive, end-to-end discovery services, including program assessment and strategy development; program management; antibody discovery and optimization; protein production, purification, and characterization; protein engineering; biochemical and cellular assay development; formulation, stability and developability studies; bioanalytical (PK and PD) assay development; and clinical candidate-validating pharmacology. Mosaic partners include biopharmaceutical companies, startup companies, and University seed and venture capital funds. For more information, please visit www.mosaicbio.com.
About Telegraph Hill Partners:
Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies. For more information, please see www.telegraphhillpartners.com.